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Abstract
Due to drawbacks of live attenuated vaccines, much more attention has been focused on screening of Brucella protective
antigens as subunit vaccine candidates. Brucella is a facultative intracellular bacterium and cell mediated immunity plays
essential roles for protection against Brucella infection. Identification of Brucella antigens that present T-cell epitopes to the
host could enable development of such vaccines. In this study, 45 proven or putative pathogenesis-associated factors of
Brucella were selected according to currently available data. After expressed and purified, 35 proteins were qualified for
analysis of their abilities to stimulate T-cell responses in vitro. Then, an in vitro gamma interferon (IFN-c) assay was used to
identify potential T-cell antigens from B. abortus. In total, 7 individual proteins that stimulated strong IFN-c responses in
splenocytes from mice immunized with B. abortus live vaccine S19 were identified. The protective efficiencies of these 7
recombinant proteins were further evaluated. Mice given BAB1_1316 (CobB) or BAB1_1688 (AsnC) plus adjuvant could
provide protection against virulent B. abortus infection, similarly with the known protective antigen Cu-Zn SOD and the
license vaccine S19. In addition, CobB and AsnC could induce strong antibodies responses in BALB/c mice. Altogether, the
present study showed that CobB or AsnC protein could be useful antigen candidates for the development of subunit
vaccines against brucellosis with adequate immunogenicity and protection efficacy.
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Introduction
Brucella species are responsible for brucellosis, a worldwide
zoonotic disease causing abortion in domestic animals (sheep,
cattle, and goats) and Malta fever in humans [1,2]. Humans are
usually infected by Brucella through contact with infected animals
or their products. Therefore, prevention of human brucellosis
depends predominantly on the control of the disease in animals.
Test and slaughter programs in conjunction with vaccination are
the most important methods for control of animal brucellosis.
Currently, B. abortus S19 or B. abortus RB51 is used to immunize
cattle, whereas the B. melitensis Rev.1 strain is used to immunize
goats and sheep in many countries. In general, the use of live
attenuated organisms as vaccines possesses some problems in
terms of safety, e.g., the potential of the organism to revert to its
original virulent forms and the shedding of the organism into the
environment. Particularly, the smooth vaccine strains induce
antibodies responses that interferes the serological diagnosis in the
test and slaughter programs. Some efforts are being made to
overcome these problems by targeted deletion of antigenic proteins
required for survival, with the aim to alleviate virulence and
provide targets for differential diagnosis of infection and
immunization [3,4,5].
Subunit vaccines have several advantages over live attenuated
vaccines: they are completely inert, definite compositions,
controllable productions and highly homogeneity. In addition,
the subunit vaccines, by inducing an immune response to a single
protein, would make it possible for the development of diagnostic
tests that could differentiate vaccinated animals from infected
animals. Subunit vaccines have been the Brucella research focus for
many years. Several protein antigens are shown to induce
protective immune response in mice model. The recent examples
include the outer membrane protein combination of Omp16 and
Omp19 for protection against B. abortus infection [6], and Omp28
with CpG oligonucleotides against B. abortus challenges [7]. Many
of these studies are focused on the limited protein antigens. For
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e29552development of subunit vaccines, screening and evaluation of
protective antigens are the most important fundamental tasks.
While many proteins have been assessed as potential protective
antigens against Brucella infection, only a few have been shown to
induce significant protection [8,9]. The degree of protection
efficiencies depends on the ability of the candidate antigens to
direct immunity towards a Th1-type response [10,11,12,13,14,15].
Therefore, proteins that induce T-cell meditated immune
responses should be candidates for such vaccines. Identification
and characterization of this type of antigens will greatly promote
discovery of subunit vaccine candidates.
As an intracellular bacterium, Brucella has some unique
characteristics. There are no any plasmids and toxins in Brucella
that play important roles in interaction between bacteria and
hosts. However, Brucella has great capabilities to survive in multiple
types of host cells [16]. The proteins that involved in intracellular
survival are important virulence factors of Brucella. For many
pathogenic bacteria, antigenic virulence proteins are usually
protective antigens. Actually, there are several proteins that
provide protection against infections also play important roles in
Brucella virulence. Therefore, virulence proteins that induce T-cell
mediated immune responses might be protective antigen candi-
dates. To identify protective antigens, in the present study, proven
or putative virulence related proteins of Brucella were selected for
antigenicity analysis. These proteins were expressed in E. coli and
purified, and then used to stimulate splenocyte from B. abortus live
vaccine S19 immunized mice. The proteins that greatly induce
secretion of IFN-c were used to immunize BALB/c mice and
tested for its capability to provide protection against B. abortus 544
infection.
Materials and Methods
Mice and Ethics Statement
Female 6-week-old BALB/c mice obtained from The Animal
Center of Military Medical Sciences. All animals were handled in
strict accordance with Experimental Animal Regulation Ordi-
nances defined by China National Science and Technology
Commission, and the animal work was approved by Beijing
Institute of Disease Control and Prevention animal ethics
committee (Ethical Approval BIDCP003-2011). Animals are
provided with humane care and healthful conditions during their
stay in the facility. All individuals who use animals receive
instruction in experimental methods and in the care, maintenance
and handling of mice, and are under the committee’s supervision.
Bacterial strains and plasmids
B. abortus 544 and S19 were cultured in Tryptic Soy Broth (TSB)
or Tryptic Soy Agar (TSA). E. coli strain ER2566 was grown on
Luria–Bertani (LB) medium. Plasmid pDONR201 (Invitrogen)
was used for GatewayH BP Reaction entry clones construction and
pHXGWA for GatewayH LR Reaction expression clones [17].
Cloning, expression, and purification of His-tagged
recombinant proteins
45 proven or putative pathogenesis-associated proteins accord-
ing to currently available data [18,19,20,21,22,23,24,25] and a
known protective antigen Cu-Zn SOD (BAB2_0535) [26] were
selected to be expressed in E. coli ER2566. Briefly, the selected
ORFs were amplified by PCR from genomic DNA of B. abortus
544 with specific primers tailed with adaptors (Table S1). Then,
the products were amplified with adaptor primer AttB1 (59-GGG
GAC AAG TTT GTA CAA AAA AGC AGG CT-39) and AttB2
(59-GGG GAC CAC TTT GTA CAA GAA AGC TGG GT-39)
to attach the recombination sequences. The amplified DNA
fragments were cloned into the pDONR201 vector by using
Gateway cloning technology. The sequences of the cloned ORFs
were verified by DNA sequencing. Then, the ORFs were sub-
cloned into expression plasmid pHXGWA and the recombinant
proteins were expressed in E. coli ER2566 as N-terminally His-
tagged fusion proteins. The expression of the recombinant proteins
was verified by SDS-PAGE. The recombinant fusion proteins
were then purified by affinity chromatography on Ni
2+-conjugated
chelating Sepharose. Proteins expressed as inclusion bodies were
solubilized with 6 M urea and refolded by serial dialysis against 4,
2, 1 and 0 M of urea in PBS. The purified proteins were finally
solubilized in PBS-1% glycine (0.01 M; pH 8.0). The purity of the
purified proteins was assessed by SDS-PAGE and the concentra-
tion was quantified.
Mice immunization, splenocyte stimulation and IFN-c
secretion detection
B. abortus live attenuated vaccine S19 was cultured in TSB at
37uC to logarithmic phase, cells were precipitated by centrifuga-
tion and then washed with PBS twice. Groups of six female 6-
week-old BALB/c mice were immunized intraperitoneally (i.p.)
with 200 ml bacterial suspension containing 5610
6 CFU of S19
per mouse or 200 ml of PBS as a control. Twenty-eight days later,
the sera were collected for determining the IgG titers of antibody
against heat-killed and sonicated S19 whole-cell antigen by
enzyme-linked immunosorbent assay (ELISA). On the 35th day,
the immunized mice and nonimmunized control mice were killed
humanely and their spleens were aseptically recovered. Single cell
suspensions of mixed splenocytes from 3 immunized mice with
higher antibodies titers or 3 control mice were obtained by
homogenization. Cells were pelleted at 1000 rpm for 10 min, and
then 10 ml red blood cell lysis buffer (150 mM NH4Cl, 1 mM
KHCO3, 0.1 mM Na2EDTA [pH 7.3]) was added to the pellet for
5 min. After washing three times with PBS, the cells were
resuspended in complete RPMI 1640 medium (GIBCO BRL)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
and 2 mM L-glutamine. The cells were cultured in 96-well plates
for 72 h at a concentration of 5610
5 cells/well in the presence of
5 mg of purified recombinant proteins, 0.5 mg of concanavalin A
(ConA, positive control) or medium alone (negative control),
respectively. Then the plates were centrifuged at 1000 rpm for
10 min, the clear culture supernatants were collected and stored at
220uC. IFN-c was determined by using an ELISA Quantikine
Mouse kit (R&D Systems). All assays were performed in triplicate
and the concentration for IFN-c in the culture supernatants was
calculated by using a linear regression equation obtained from the
absorbance values of the standards according to the manufactur-
er’s procedures.
Immunization and protection experiments
Female 6-week-old BALB/c mice were immunized by the
intraperitoneal route with purified recombinant proteins. Briefly,
mice were immunized with 200 ml of recombinant proteins (30 mg)
or PBS (negative control) mixed with complete Freund’s Adjuvants
(CFA, Sigma) on day 0 and with incomplete Freund’s Adjuvants
(IFA, Sigma) on day 15. The positive control group was
immunized on day 15 with 1610
5 CFU of B. abortus S19 mixed
with IFA. 30 days after the last immunization, mice were
challenged i.p. with 2610
4 CFU of B. abortus virulent strain 544.
30 days post the challenge, mice were killed by cervical dislocation
and spleens were removed aseptically and homogenized with PBS
containing 0.1% Triton X-100. The homogenates were serially
CobB or AsnC Confers Protection against Brucella
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days of incubation at 37uC.
Humoral immune responses
Sera for antibody response detection were obtained at 0, 15, 30
and 45 days after the first immunization. Serum reaction against
purified recombinant proteins were determined by indirect ELISA
as described previously [8,9].
Statistical analysis
Cytokine production in vitro was expressed as mean cytokine
concentration 6 SD. The protective efficiency was expressed as
the mean log10 CFU 6 SD. The differences between groups were
analyzed by ANOVA followed by Tukey’s honestly significant
difference post test comparing all groups to one another. For
ANOVA, P values of ,0.05 were considered statistically
significant.
Results
Cloning, expression and purification of virulence-
associated proteins of Brucella
According to currently available data, 45 proven or putative
pathogenesis-associated factors were selected (Table S1). In
addition, a known protective antigen Cu-Zn SOD (BAB2_0535)
was also cloned and expressed. The selected 46 ORFs were
amplified by PCR and cloned into the pDONR201 vector by
using Gateway cloning technology. The sequences of the cloned
ORFs were verified by DNA sequencing. Then, the amplified
DNA sequences of the ORFs for these proteins were cloned into
pHXGWA to generate expression plasmids that were then
transformed into E. coli ER2566 to express the recombinant
fusion proteins with His tags. According to the SDS-PAGE
analysis, 35 ORFs were successfully expressed, with 19 (54.3%) of
them being expressed as inclusion bodies (data not shown). All the
proteins were purified by Ni
2+-conjugated chelating chromatog-
raphy. Proteins expressed as inclusion bodies were solubilized with
urea and refolded by dilution after being purified. All purified
proteins were finally solubilized in PBS–1% glycine. The purity of
the purified proteins was assessed by SDS-PAGE (Figure 1) and
the concentration was quantified (data not shown). In the end, 35
proteins were successfully purified and qualified for subsequent
analysis of their abilities to stimulate T-cell responses (Table S1).
Proteins that induce IFN-c secretions in splenocytes of
S19 immunized mice
To assess the T-cell immunity inducing activity of the 35
proteins, sensitized splenocytes were firstly prepared. BALB/c
mice were i.p. immunized with live vaccine strain S19. On the
28th day post the immunization, sera from immunized mice were
collected and the IgG levels were measured by ELISA. The results
showed the IgG titer reached at least 10000 (data not shown),
suggesting that the single injection induced immune responses in
mice. 35 days post the immunization, spleens were removed and
cells were isolated. The splenocytes were stimulated with each of
the purified recombinant proteins, complete medium (negative
control) or ConA (positive control), and secretion of IFN-c was
assayed. As shown in Figure 2, compared with cells from control
group immunized with PBS, splenocytes from S19-immunized
mice secreted significant higher levels of IFN-c (P,0.001) when
stimulated by BAB1_0560, BAB1_1108, BAB1_1316,
BAB1_1688, BAB2_0059, BAB2_0191, and BAB2_0423, similar-
ly with the known protective antigen Cu-Zn SOD. The results
indicated that these 7 proteins were good candidates for further
protection analysis (Table 1).
CobB and AsnC induce protective immune responses
against B. abortus 544 challenge
Then, the 7 proteins were used to immunize BALB/c mice and
their protection efficiencies were evaluated. At 45 days after the
first immunization, the vaccinated mice were challenged with
virulent strain B. abortus 544, and 30 days post the challenge,
Brucella in spleen were isolated and enumerated. Protection
efficiency was defined as the difference between the numbers of
viable bacteria recovered from spleens of immunized mice and
those recovered from spleens of mice receiving PBS. Mice
immunized with BAB1_1316 (CobB) or BAB1_1688 (AsnC) plus
adjuvant exhibited a significant degree of protection (P,0.001)
when compared with controls receiving PBS, with 1.16 and 1.89
units of protection, respectively (Table 2). As expected, the known
protective antigen Cu-Zn SOD and the license vaccine S19 offer
significant protection (1.30 and 1.02 units, respectively). The
remaining 5 recombinant proteins could not provide significant
protection against virulent B. abortus challenge (Table 2).
CobB and AsnC induce antibodies responses
To further evaluate the immunogenic characteristics of CobB
and AsnC, the production of antigen-specific antibodies was
measured in the sera of the immunized mice by indirect ELISA.
For comparison, the known protective antigen Cu-Zn SOD
was also included. As shown in Figure 3, immunization with
CobB or AsnC plus adjuvant elicited a humoral immune response
that was detectable 15 days (IgG mean titer: 6400 and 8000,
respectively) after the first immunization and reached a maximum
at day 30 post the vaccination (IgG mean titer: 160000 and
220000, respectively), higher than the positive control protein
Cu-Zn SOD. The results indicated that immunization with CobB
or AsnC plus adjuvant could also induce humoral immune
response.
Figure 1. SDS-PAGE of the recombinant proteins. The expression
of recombinant fusion proteins were analyzed by SDS-PAGE. M,
molecular size protein markers; lane 1–12, the purified fusion proteins:
BAB1_0063, BAB1_0116, BAB1_0381, BAB1_0512, BAB1_0553,
BAB1_0560, BAB1_0597, BAB1_0722, BAB1_0812, BAB1_0917,
BAB1_1108, BAB1_1124.
doi:10.1371/journal.pone.0029552.g001
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Brucella is a genus of intracellular pathogens that preferentially
infect macrophages. Successful elimination of intracellular path-
ogens relies on capability of vaccines to generate potent cell
mediated immunity. In particular, Th1 immune responses
characterized by production of gamma interferon (IFN-c) are
associated with protective immunity to Brucella [27,28]. Thus
identification and characterization of Brucella antigens which
present T-cell epitopes to the host will contribute greatly to
development of subunit vaccines against Brucella infection.
The availability of complete bacterial genome sequences makes
a push for reverse vaccinology to be put into practice [29,30].
Immunoproteomics and protein microarrays were used to identify
novel immunogens that induced humoral immune responses in a
high-throughput manner [9,31,32,33,34]. However, the approach
to identify T-cell antigens on a large scale is just being underway
[9,35]. In this study, proteins associated with Brucella pathogenesis
were expressed in E. coli. Then, their abilities to induce T-cell
responses were tested. For the proteins that could stimulate strong
IFN-c responses, immunogenicity and protective ability were
further evaluated. This reverse vaccine methodology is ideal for
the rapid identification of T-cell antigens and development of
subunit vaccines for brucellosis.
In this study, 45 proven or putative pathogenesis-associated
proteins were selected for in vitro expression. Previous studies
demonstrated that vaccination of mice with E. coli expressing
Brucella Cu-Zn SOD was able to induce antigen specific Th1
immune responses and conferred a significant level of protection
against virulent B. abortus challenge [26]. So Cu-Zn SOD was also
expressed and used as positive experimental control. In the end, 35
of 45 proteins were successfully expressed and purified. Among
these 35 proteins, 7 proteins could stimulate stronger IFN-c
responses in mice immunized with S19, indicating their abilities to
induce T-cell responses. The reasons for the other 28 proteins not
recognized as T-cell immunogens in this study include several
possibilities. First, these proteins could not induce T-cell responses
in deed. Second, in our study, the expressed proteins were
recombinant and had lost their native conformations that might be
important for T-cell response induction. Third, in the in vitro T-
cell stimulation assays, the same concentration of each protein was
used. But the optimal concentration for in vitro stimulation may be
different for these proteins. Thus our study may ignore some
proteins which also induce T-cell responses.
Very interestingly, we found that some proteins induced greatly
higher levels of IFN-c in splenocytes of PBS immunized mice than
those of S19 immunized ones. For example, BAB2_0431 and
BAB1_0917 induced 2.26 and 2.31 folds higher IFN-c in PBS
immunized mice than that in S19 immunized ones. This was not
observed in our previous studies on Yersinia pestis, where all tested
proteins induced higher or identical levels of IFN-c in vaccine
strain immunized mice than control mice [36]. We thought there
might be two possibilities: interference of host immune response
and acquired immune tolerance. Brucella is an intracellular
bacterium that could cope with host immune response for its
survival. A Toll/Interleukin-1 receptor (TIR) domain containing
protein mimics TcpB has been shown to inhibit TLR2 and TLR4
mediated NF-kB activation. In vivo mouse studies indicated that
tcpB mutant was defective in systemic spread in the early stages of
infection [37]. It is possible that some of these proteins interfere
with the secretion of IFN-c. Acquired immune tolerance might be
another reason, which is characterized by a specific non-reactivity
to a given antigen that would likely induce cellular or humoral
immunity in other circumstances. It will be very interesting to
Figure 2. IFN-c secretion by splenocytes stimulated with the recombinant B. abortus proteins. Spleen cells from mice immunized with S19
or PBS were stimulated in vitro with recombinant proteins, ConA (positive control), or complete medium (negative control). Supernatants were
collected and IFN-c was determined by using an ELISA Quantikine Mouse kit (R&D Systems). All assays were performed in triplicate and the
concentrations for IFN-c in the culture supernatants were calculated by using the quantification formula. Significant differences between S19-
immunized mice and PBS-immunized mice are indicated as follows: *, P,0.001.
doi:10.1371/journal.pone.0029552.g002
Table 1. Proteins that induced strong T-cell responses in
mice immunized with S19.
Locus
Protein
name
The location
of Protein Description
BAB1_0560 - Cytoplasm phosphomannomutase
BAB1_1108 - Unknown predicted acyl-CoA transferase
BAB1_1316 CobB Cytoplasm cobyrinic acid a,c-diamide synthase
BAB1_1688 AsnC Unknown transcriptional regulatory protein,
AsnC family
BAB2_0059 VirB10 Unknown channel protein virB10 homolog
BAB2_0191 - Cytoplasm HAD superfamily protein involved
in N-acetyl-glucosamine catabolism
BAB2_0423 GntR Cytoplasm transcriptional regulator, gntR
family
doi:10.1371/journal.pone.0029552.t001
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regulation or immune tolerance.
The protective efficiencies of 7 recombinant proteins that could
induce T-cell responses were evaluated in mice model. At 4 weeks
post challenge, mice immunization with BAB1_1316 (CobB) or
BAB1_1688 (AsnC) plus adjuvant demonstrated 1.16 and 1.89 units
of protection (P,0.001) compared with PBS controls. However,
different from previously studies, license vaccine S19 only showed
1.02 units of protection [6,8]. This difference may be attributed to
the distinction in the status of mice and challenging strain 544. In
the present study, we found that the bacterial load in the PBS group
is at least 1 log higher than that observed in other studies, implying
the possibility of increased virulence of strain 544. On the other
hand, the spontaneous mutation of some genetic factors in mice
might also affect the susceptibility of the mice to intracellular
pathogens. For example, mutations in Nramp1 gene influence
innate resistance to Mycobacterium species [38]. Spontaneous
mutations in these genes might affect the sensitivity of mice to the
challenging strain 544. Therefore, both the genetic background
alterations of the mice and/or the virulence of challenging strain
544 could affect the bacterial load in the spleen.
In the present study, the known protective antigen Cu-Zn SOD
was also used as positive control, using the same immunization
programs with candidate proteins. Results showed that Cu-Zn
SOD conferred a similar degree of protection with CobB, being
higher than that of S19. In general, acellular vaccines such as
purified recombinant proteins and synthetic peptides are usually
unable to confer a higher degree of protection than live attenuated
vaccines [39]. The reduced effectiveness of the acellular vaccines
might be related to inadequate processing and presentation of the
antigen. However, live attenuated vaccine strains could infect the
host cells efficiently and produce endogenous antigens in antigen-
presenting cells. Right adjuvant and adequate delivery systems can
augment cell-mediated immune responses to the target antigen
and enhance the protection efficiency of subunit vaccines.
Although in most cases, live attenuated vaccines confer better
protection against Brucella infection than subunit vaccines.
Actually, Brucella subunit vaccines that have similar or higher
protection efficiency than live attenuated vaccine strains were also
observed in recent reports [40,41]. The reasons for the higher
protection efficiency of subunit vaccines might include the high
concentration of immunization antigens, the repeated immuniza-
tion and the use of adjuvant or delivery system that induce great
protective immune responses.
Table 2. Protection against B. abortus 544 infection induced
by recombinant B. abortus proteins immunization.
Vaccine (n=5) Adjuvant
log10 B. abortus at
spleen
Units of
protection
a
BAB1_1316 CFA/IFA 5.7160.32 1.16
*
BAB1_1688 CFA/IFA 4.9860.72 1.89
*
BAB1_0560 CFA/IFA 6.6860.30 —
BAB1_1108 CFA/IFA 6.4860.21 —
BAB2_0059 CFA/IFA 6.2660.61 —
BAB2_0423 CFA/IFA 6.5860.14 —
BAB2_0191 CFA/IFA 6.5260.70 —
Cu-Zn SOD CFA/IFA 5.5760.28 1.30
*
S19 IFA 5.8560.85 1.02
*
PBS CFA/IFA 6.8760.24 0
aUnits of protection were obtained by subtracting the mean log10CFU/spleen of
the vaccinated group from the mean log10CFU/spleen of the control (PBS)
immunized group.
*p value,0.05.
doi:10.1371/journal.pone.0029552.t002
Figure 3. Humoral immune response induced by CobB, AsnC, and Cu-Zn SOD. BALB/c mice (n=5) were inoculated intraperitoneally with
purified recombinant proteins plus adjuvant. At 0, 15, 30, and 45 days post the immunization, serum samples were collected and IgG antibody titers
were determined by ELISA. The values are mean titers 6 SD of antibodies from the five mice.
doi:10.1371/journal.pone.0029552.g003
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related to vitamin B12 synthesis, and BAB1_1688 (AsnC) is a
member of the transcriptional regulatory proteins, both of which
have recently been demonstrated to be involved in the
pathogenesis of Brucella [18]. Brucella mutant deficient for either
of the two proteins could not establish infection at early infection
stages, indicating that the two proteins are important for Brucella
early stage of infection. From this point of view, it could be
putatively predicted that virulence proteins that play essential roles
at early infection stages are more possibly protective antigens for
Brucella. To further evaluate the vaccine potential of recombinant
proteins CobB and AsnC, the antibodies response was also
investigated. Results showed that immunization with CobB or
AsnC plus adjuvant could induce remarkable titers of total IgG,
higher than the positive control protein Cu-Zn SOD. Thus
immunization of CobB or AsnC plus adjuvant could induce both
humoral and cellular immune responses.
To further confirm the vaccine candidate property of the two
proteins, the sequences of them were compared among different
Brucella species. A BLAST analysis revealed that CobB and AsnC
were highly conserved among different Brucella species in term of
both nucleotide acid and amino acid (data not shown). The results
indicated that CobB and AsnC would be suitable candidates for
developing vaccines against different Brucella infections.
In conclusion, our results indicate that pathogenesis-associated
proteins CobB and AsnC could be potential protective antigens for
the development of subunit vaccines against brucellosis since they
could elicit both humoral and cellular immune responses, and
confer protection against virulent B. abortus challenge. Further
studies will be focus on develop efficient adjuvant or antigen
delivery systems to further evaluate the protective immunity of
CobB and AsnC.
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